A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
To evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution for the treatment of secondary hyperparathyroidism (SHPT) in pediatric subjects 0 to 9 years of age with stage 5 chronic kidney disease (CKD), receiving peritoneal dialysis (PD) or hemodialysis (HD).
